ReviewTargeted oncology2015
Transforming growth factor-beta and its implication in the malignancy of gliomas.
Review in Targeted oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 66 citations in OpenAlex.
- Article
- Targeting TGF-β signaling in glioblastoma: therapeutic implications and novel drug development strategies.Brain tumor pathology · 2025Review
- Revisiting ABC Transporters and Their Clinical Significance in Glioblastoma.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Myosin light chain phosphatase is a downstream target of Rho-kinase in endothelin-1-induced transactivation of the TGF-β receptor.Cell biochemistry and biophysics · 2024Article
- vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target.Antibodies (Basel, Switzerland) · 2024Review
- Article
- Role of Non-Coding RNAs in TGF-β Signalling in Glioma.Brain sciences · 2023Review
- Article
- Natural Killer Cell-Based Immunotherapy against Glioblastoma.International journal of molecular sciences · 2023Review
- Insight into lipid-based nanoplatform-mediated drug and gene delivery in neuro-oncology and their clinical prospects.Frontiers in oncology · 2023Review
- TGF-β based risk model to predict the prognosis and immune features in glioblastoma.Frontiers in neurology · 2023Article
- Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade.Cancers · 2021Review
- TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT.Neuro-oncology · 2021Article
- Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future.Stem cell research & therapy · 2021Review
- Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development.Cells · 2021Review
- Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma.Frontiers in oncology · 2021Review
- RNA m1A Methyltransferase TRMT6 Predicts Poorer Prognosis and Promotes Malignant Behavior in Glioma.Frontiers in molecular biosciences · 2021Article
- Transforming Growth Factor-Beta-Regulated LncRNA-MUF Promotes Invasion by Modulating the miR-34a Snail1 Axis in Glioblastoma Multiforme.Frontiers in oncology · 2021Article
- Immune response in glioma's microenvironment.Innovative surgical sciences · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant gliomas are the most common type of primary malignant brain tumors. They are characterized by enhanced growing capabilities, neoangiogenic proliferation, and extensive infiltration of the brain parenchyma, which make their complete surgical resection impossible. Together with transient and refractory responses to standard therapy, these aggressive neoplasms are incurable and present a median survival of 12 to 14 months. Transforming growth factor-beta (TGF-β) is a pleiotropic cytokine of which two of the three isoforms expressed in humans have been shown to be overexpressed proportionally to the histologic grade of glioma malignancy. The increase of chromosomal aberrations and genetic mutations observed in glioma cells turns TGF-β into an oncogene. For that reason, it plays critical roles in glioma progression through induction of several genes implicated in many carcinogenic processes such as proliferation, angiogenesis, and invasion. Consequently, investigators have begun developing innovative therapeutics targeting this growth factor or its signaling pathway in an attempt to hinder TGF-β's appalling effects in order to refine the treatment of malignant gliomas and improve their prognosis. In this paper, we extensively review the TGF-β-induced oncogenic pathways and discuss the diverse new molecules targeting this growth factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.